Arvinas' ARV-102 Shows Oculomotor and Biomarker Improvements in Parkinson's Phase 1
ARVN is trading near its 52-week low of $6.97 (7.9% above the low).
Summary
Arvinas presented final Phase 1 data for ARV-102, its oral PROTAC LRRK2 degrader, at the MDS 2026 congress. The trial in 24 Parkinson's patients showed dose-dependent improvements in saccadic hypometria (an objective eye-movement measure) and reductions in LRRK2 CSF biomarkers, with correlations to endolysosomal, neuroinflammatory, and synaptic pathway changes. This is the first disclosure of these oculomotor and biomarker correlation data, building on earlier AD/PD 2026 results that showed brain penetration and LRRK2 degradation. The findings support continued clinical evaluation of ARV-102 in neurodegenerative diseases, though the study was not designed to assess clinical efficacy. Arvinas has a market cap around $478M and recently reported strong Q2 2026 financials driven by the VEPPANU deal, extending cash runway. The data add to a pipeline that includes ARV-6723, which dosed its first patient in late September.
At the time of this announcement, ARVN was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $478M. The 52-week trading range was $6.97 to $14.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.